CTOs on the Move

Patara Pharma

www.patarapharma.com

 
Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.
  • Number of Employees: 1K-5K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Patara Pharma raised $26M on 10/12/2015

Similar Companies

Rocket Pharmaceuticals

Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company advancing numerous gene therapies that could cure rare childhood diseases. Rocket places enormous value on people and takes team member progress and well-being just as seriously as the progress and well-being of its pipeline. We are looking for hands-on team players that enjoy collaborating with colleagues who share a passion for seeking gene therapy cures for devastating diseases and making a difference for patients. Become an integral part of a small, highly productive team and help grow an entrepreneurial, scientifically driven organization that is increasingly recognized as a leading biotechnology innovator. In addition to a competitive compensation package featuring a generous 401K match and stock options, positions include excellent health benefits.

Aragen Biosciences

Aragen Biosciences is a Morgan Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aristea Therapeutics

Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases.

UVJ technology

UVJ technology is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avalo Therapeutics Inc

Avalo is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.